跳到主要内容

新闻与日历

新闻: 截至 2026-10-10
这些标记是什么意思

重要性是模型对已发布报道给出的 1–5 分,不是对市场的预测。

已排定事件行上的影响是公司显著度层级(高/中由图谱中心度与规模判定;低仅用于人工整理的次要事件),不是对波动幅度的预测。

标记为已确认的财报日期,是 Yahoo Finance 认定由公司确认的;预估表示尚未公布。未加标记的行没有可查的出处记录。

经济数据发布属于宏观、不归属任何产业,因此在任何视图下都会保留。没有数值的发布表示尚未公布,页面会直说,而不是显示为零。

涵盖被追踪公司的即将到来的事件;已过去的事件会归档,并在可得时补上结果——这些结果都经人工整理并附引用,绝不杜撰。没有结果的历史行会显示“结果待定”。

解禁或指数调整的行会多出一行算术——将变得可卖出的股数,或指数基金必须买入的股数,以占流通股的比例表示——依据招股说明书或指数编制方法读出,两个数字都在该行注明出处。它陈述的是机制,不是价格走势。由 IPO + 180 天推算出的解禁日期会一直标为预估,直到公司自己说明为止。

未来

已排定 · 今天与明天 · 日历更新于 2026-10-12

10月12日周一 · 今天

10月13日周二

过往

已发布 · 最新在前

8月3日周一

合作

11:01
GlobeNewswire

X-energy, SGL Carbon Announce Capacity Expansion for Nuclear-Grade Graphite

X-energy and SGL Carbon announced an agreement that would expand the supply chain for a critical long-lead material, supporting execution of X-energy's 11+ GW commercial pipeline. The release describes facility upgrades at SGL's Chedde, France site and expanded U.S. machining capacity.

大盘 打开原文 ↗

7月31日周五

产品

18:24
Yahoo Finance

Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial

Novo Nordisk shares fell after a late-stage trial of ziltivekimab was unable to reduce major adverse cardiovascular events compared with a placebo, a setback for the company's cardiovascular pipeline.

大盘 打开原文 ↗

7月30日周四

财报

20:15
GlobeNewswire

Eversource Energy Reports Second Quarter 2026 Results

Eversource Energy reported second-quarter 2026 "GAAP earnings of $53.7 million, or $0.14 per share," and "Non-GAAP recurring earnings totaled $329.1 million, or $0.87 per share." The company reaffirmed "2026 non-GAAP recurring earnings of between $4.57 per share and $4.72 per share" and a "cumulative long-term earnings per share growth rate within the range of 5 to 7 percent through 2030."

大盘 打开原文 ↗

财报

20:04
SEC EDGAR

First Solar, Inc. Announces Second Quarter 2026 Financial Results and Reaffirms Guidance

First Solar reported Q2 2026 net sales of $1.06 billion, "a decrease of 4% year-over-year," and net income of $423 million, or $3.92 per diluted share, versus $342 million or $3.18 per diluted share a year earlier. Adjusted EBITDA was $644 million. The company reaffirmed its 2026 guidance and reported a "Contracted sales backlog of 45.1 GW as of June 30, 2026," noting it "surpassed 100 GW of cumulative module sales globally."

大盘 打开原文 ↗

财报

13:38
GlobeNewswire

Sanofi's half-year financial report for 2026

Sanofi announced the availability of its half-year financial report for the period ended June 30, 2026, filed with French and US regulators. The release points to Q2 results reporting "Q2 sales growth of 17.8% at CER" and "business earnings per share (EPS) of EUR 2.09," with "2026 guidance upgraded."

大盘 打开原文 ↗

原始消息流

所有到达的消息 · 7 天